Zynerba Pharmaceuticals, Inc. ZYNE Balance Sheet

Zynerba pharmaceuticals, inc. (ZYNE)

Balance Sheet / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Dec'14
Assets
Current assets:
Cash and cash equivalents
60,638	70,063	77,547	88,661	68,299	59,763	66,177	43,115	52,131	62,510	66,251	70,179	77,493	30,965	31,780	32,133	36,809	41,513	44,806	5,742	9,330
Incentive and tax receivables
12,906	14,613	13,446	3,407	3,395	3,444	3,095	3,961	4,044	3,983	3,617	3,971	3,867	3,613	2,281	1,692	356	356	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,950	1,080
Prepaid expenses and other current assets
1,474	2,378	2,831	1,501	2,524	3,747	3,413	1,962	1,788	1,733	3,010	2,307	2,002	1,830	1,464	1,768	1,359	1,545	2,059	-	1,183
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,681	-
Total current assets
75,020	87,056	93,825	93,570	74,219	66,955	72,685	49,039	57,965	68,227	72,879	76,458	83,363	36,410	35,526	35,594	38,526	43,415	46,865	9,374	11,594
Property and equipment, net
587	362	339	332	346	371	248	273	155	164	190	177	198	143	304	209	223	227	229	103	19
Incentive and tax receivables
571	-	-	1,459	692	-	-	2,056	1,118	-	-	2,456	1,141	-	-	-	-	-	-	-	-
Right-of-use assets
287	345	152	206	258	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	-	834	662	662	0	0	0	0	463	0	352	0	0	2	2
Total assets
76,466	87,764	94,317	95,569	75,517	67,327	72,934	52,203	59,901	69,054	73,069	79,092	84,703	36,554	36,294	35,803	39,102	43,643	47,095	9,480	11,616
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
3,328	4,740	3,302	3,742	3,947	4,461	3,553	6,379	4,605	3,355	3,116	2,024	996	1,848	1,694	2,681	989	823	615	1,775	313
Accrued expenses
6,676	7,073	5,842	6,027	3,268	5,264	5,415	4,910	4,131	3,915	4,479	5,004	5,110	4,284	2,882	1,517	1,090	2,272	1,207	1,262	1,711
Lease liabilities
252	243	159	216	249	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue
-	-	-	-	-	-	171	-	171	171	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue
-	-	-	-	-	-	-	-	-	-	833	833	833	833	370	833	833	841	890	1,089	1,120
Total current liabilities
10,257	12,058	9,303	9,985	7,465	9,725	9,141	11,290	8,909	7,442	8,429	7,863	6,941	6,966	4,947	5,032	2,914	3,937	2,713	4,128	3,145
Lease liabilities, long-term
44	109	-	-	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue, long-term
-	-	-	-	-	-	-	833	662	662	-	-	-	-	-	-	-	-	-	-	-
Commitments and contingencies (note 11)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Deferred grant revenue, long-term
-	-	-	-	-	-	-	-	-	-	-	-	-	-	463	-	-	-	-	-	-
Total liabilities
10,301	12,167	9,303	9,985	7,486	9,725	9,141	12,124	9,571	8,104	-	-	-	6,966	5,410	-	-	-	-	-	-
Series 1 convertible preferred stock, $0.001 par value; 7,807,502 shares authorized; 6,964,053 shares issued and outstanding at December 31, 2014
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,522	16,522
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	-	0
Common stock, $0.001 par value; 200,000,000 shares authorized; 23,572,391 shares issued and outstanding at March 31, 2020 and 23,211,391 shares issued and outstanding at December 31, 2019
23	23	23	23	21	17	17	13	13	13	13	13	13	9	9	9	9	9	9	2	2
Additional paid-in capital
229,314	226,409	225,110	223,734	195,048	175,476	173,877	142,359	140,603	138,916	134,489	132,766	130,976	75,545	69,946	63,853	63,040	62,276	61,512	1,975	1,975
Accumulated deficit
-163,173	-150,835	-140,120	-138,174	-127,039	-117,892	-110,101	-102,294	-90,287	-77,980	-69,862	-61,551	-53,227	-45,968	-39,071	-33,090	-26,861	-22,580	-17,140	-13,147	-10,028
Total stockholders' equity
66,164	75,596	85,013	85,583	68,030	57,601	63,793	40,078	50,330	60,949	64,640	71,229	77,762	29,587	30,883	30,771	36,188	39,705	44,381	-11,170	-8,051
Total liabilities and stockholders' equity
76,466	87,764	94,317	95,569	75,517	67,327	72,934	52,203	59,901	69,054	73,069	79,092	84,703	36,554	36,294	35,803	39,102	43,643	47,095	9,480	11,616